Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 6/20 | 0.50 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | CDK4 | P11802 | 3/20 | 0.50 |
| ▸ | CDK7 | P50613 | 3/20 | 0.50 |
| ▸ | CDK9 | P50750 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205109 | 0.85 | CDK2 (0.55) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL8215036 | 0.85 | MKNK1 (0.54) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL8312330 | 0.84 | JAK2 (0.52) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL4062587 | 0.84 | PLK4 (0.55) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL14020993 | 0.84 | PIK3CA (0.55) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL1512786 | 0.84 | PIK3CA (0.55) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL8307949 | 0.84 | MAPK8 (0.63) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL8314274 | 0.84 | JAK2 (0.72) | JAK2CDK2CDK9JAK3HDAC3 | |
| SCHEMBL14063804 | 0.83 | CDK2 (0.51) | JAK2IKBKBCDK2CDK1AURKA | |
| SCHEMBL8315359 | 0.83 | CDK2 (0.55) | JAK2IKBKBCDK2CDK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | JAK2 1695/4885IKBKB 875/4885CDK2 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.